论文部分内容阅读
Recent CV safety trialsEMPA-REG Outcome Primary end-point: 3-point MACEWhat is new for the EMPA-REG OUTCOME trial· Renal protection results· Asian data· Detailed stroke analysis· New indications for useEMPA-REG Outcome Renal end-points· Empagliflozin:-Protected eGFR vs placebo over 4 years-Reduced progression of albuminuria-Reduced renal composite outcomesEmpagliflozin:Long term protection of eGFREMPA-REG OUTCOME Asian Sub-set analysis